Annual International Conference on ADHD Hosted by CHADD, ADDA and ACO Provides Trusted Information, Guidance and Support to the ADHD Community

LANHAM, Md., Nov. 07, 2024 (GLOBE NEWSWIRE) — The leading experts in attention-deficit/hyperactivity disorder (ADHD) will convene to share trusted information about the latest research, treatment options, and practical guidance with the ADHD community at the Annual International Conference on ADHD 2024, November 14 through 16, in Anaheim, California. This premier event is hosted by…

Read More

Is ADHD Really a ‘Superpower’?

In the past three weeks, at least four people have asked me if I’ve listened to the song “ADHD” by Paris Hilton. The single from her new album is a heavily auto-tuned account of her struggles with the disorder she was diagnosed with as an adult, including racing thoughts, inability to sleep, and feeling like…

Read More

“I Have Adult ADHD. My Wife Suffers From It.”

Key points: The effects of ADHD on adults with the diagnosis are well documented. The effects of a partner’s ADHD on the non-ADHD partner or spouse are less known. A recent study showed the difficulties reported by non-ADHD wives living with husbands with ADHD. Psychoeducation has been advised for ADHD-affected couples but more programs are…

Read More

Study delves into the lives of neurodivergent psychiatrists

Groundbreaking research exploring the experiences of autistic psychiatrists has revealed that psychiatrists who are unaware that they themselves are autistic may fail to recognise the condition in their patients. The study, conducted by researchers from University College Dublin, London South Bank University, Brighton and Sussex Medical School, is the first of its kind to delve…

Read More

How ADHD Affects Clinical Practice

Godfrey-Harris and Shaw (2023) define Attention Deficit/Hyperactivity Disorder (ADHD) as “a form of neurodivergence, characterized by lifelong differences in attention, impulsivity, and hyperactivity.” While there are considerations for each ADHD subtype, this article will only focus on general presentations as many co-morbidities may occur between the subtypes.

Read More

Viloxazine ER for ADHD Reduces Weight Among Adults With Overweight, Obesity

Relative to placebo, Viloxazine extended-release (viloxazine ER) treatment for attention-deficit hyperactivity disorder (ADHD) is associated with significant weight loss – particularly among adults with overweight and/or obesity at baseline. These study results were presented at Psych Congress 2024, held from October 29 to November 2, 2024 in Boston, Massachusetts.

Read More